The 2026 Trial of Phyllanthus Emblica and Tinospora for Acne: Study Design and Evidence Limits for Adults With Persistent Acne

There is no verifiable 2026 clinical trial of Phyllanthus emblica (amla, or Indian gooseberry) combined with Tinospora for acne. As of September 5, 2026, searches of ClinicalTrials.gov, the Clinical Trials Registry–India, and indexed literature turn up no such study, so any article or product page citing a "2026 trial" of this pair is describing research that cannot currently be documented. What does exist is older and thinner: one small placebo-controlled trial from 1995 in which an amla-containing formulation helped and a Tinospora-containing one did not, plus animal work and a topical sebum study. Adults with persistent acne should read claims about this herb combination against that limited record, not against a headline trial that has not surfaced.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What the "2026 trial" claim actually rests on
The closest real human trial: one study from 1995
What Tinospora specifically has shown for acne
Safety: the liver question with oral Tinospora
What adults with persistent acne can practically do
Frequently Asked Questions

What the "2026 trial" claim actually rests on

The premise of the title cannot be confirmed. No registered or published 2026 trial pairs Phyllanthus emblica with Tinospora for acne in any of the standard registries or databases. That does not prove no study is underway somewhere unregistered, but it means there is no study design to evaluate, no participant numbers, no endpoints, and no results.

This matters because supplement marketing often anticipates evidence. A claim built on a trial nobody can locate should be treated as a claim without a trial. If a specific registration number or journal citation appears later, it can be checked; until then, the evidence base is what is described below.

The closest real human trial: one study from 1995

The best available human evidence comes from a double-blind, randomised, placebo-controlled trial by Paranjpe and Kulkarni, published in the Journal of Ethnopharmacology in 1995. It randomised 82 acne vulgaris patients to one of four oral Ayurvedic formulations or placebo for six weeks. Only one formulation beat placebo. Sunder Vati — 30 mg of Emblica officinalis (Phyllanthus emblica) fruit per tablet, alongside Holarrhena antidysenterica, Embelia ribes, and ginger — significantly reduced lesion counts.

The other three formulations, including Tinospora-containing guduchyadi preparations, showed no significant change from baseline. Two limits deserve emphasis. First, Sunder Vati is a four-herb blend, so the trial cannot attribute the benefit to amla alone. Second, this is a single small six-week study from three decades ago that has never been independently replicated.

What Tinospora specifically has shown for acne

Tinospora (guduchi or giloy, a climbing shrub used widely in Ayurvedic medicine) has essentially no positive human acne evidence. The Drugs.com Tinospora monograph, summarizing the clinical literature, records that Tinospora given alone for acne was no more effective than placebo — and that remains the only human acne evidence for the herb currently indexed.

The two herbs have been formally studied together only in animals. A 2021 study in the Journal of Ayurveda and Integrative Medicine tested phyllanthus emblica and Tinospora cordifolia formulations in immunocompromised mice, measuring immunomodulation — not acne, and not in humans.

Safety: the liver question with oral Tinospora

Adults considering oral Tinospora should know that its hepatic safety profile is under formal review. NIH's LiverTox database documents Tinospora cordifolia and reviews reported cases of herb-induced liver injury associated with Tinospora products.

That risk profile changes the calculus for a condition like persistent acne, which has well-studied prescription options with known safety monitoring. Taking an oral herb with documented liver-injury reports, for a benefit no human trial has demonstrated, is a poor trade. Anyone who does use Tinospora and develops fatigue, dark urine, or yellowing skin or eyes should stop it and see a doctor.

What adults with persistent acne can practically do

The topical angle for amla is more modest and better bounded. One facial-skin study of a Phyllanthus emblica toner measured an average anti-sebum effect of 23.5% four hours after application — relevant to oily, acne-prone skin, but a sebum measurement, not a reduction in actual acne lesions. A practical reading of the whole record: The strongest human signal for either herb remains a single 82-person, six-week trial from 1995 in which only the amla-containing blend worked — a preliminary result, not a foundation for a treatment decision.

Treat any "2026 combined-herb trial" claim as undocumented until a registration or publication can be produced.
Do not expect oral Tinospora to help acne; its only human acne data showed no benefit over placebo, and liver-injury cases are on record.
If amla interests you, the topical sebum-control route carries less systemic risk than oral blends.
For persistent adult acne, evidence-backed prescription options (retinoids, hormonal therapy, antibiotics where appropriate) remain the treatments a dermatologist can actually dose and monitor.

Frequently Asked Questions

Is there any registered 2026 trial of Phyllanthus emblica and Tinospora for acne?

No. As of September 5, 2026, no such trial appears on ClinicalTrials.gov, in Clinical Trials Registry–India results, or in indexed literature.

Has Tinospora ever worked for acne in a human study?

No. The only indexed human acne evidence, summarized in Drugs.com's monograph, found Tinospora alone no better than placebo.

Did amla itself reduce acne in the 1995 trial?

Not in isolation. The effective formulation, Sunder Vati, combined amla with three other herbs, so the benefit cannot be attributed to amla alone.